First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. (IXOGoo1)

This study is currently recruiting participants.
Verified February 2014 by AHS Cancer Control Alberta
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT01129310
First received: May 21, 2010
Last updated: February 28, 2014
Last verified: February 2014

May 21, 2010
February 28, 2014
July 2010
April 2014   (final data collection date for primary outcome measure)
Overall Response Rate and dose limiting toxicity [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Overall Response Rate and dose limiting toxicity [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01129310 on ClinicalTrials.gov Archive Site
Progression Free Survival, overall survival, death, alterations in quality of life outcomes [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Progression Free Survival, overall survival, death, alterations in quality of life outcomes [ Designated as safety issue: No ]
Not Provided
Not Provided
 
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
A Multicentre, Open-label Phase II Study of Irinotecan, Capecitabine(Xeloda), and Oxaliplatin (IXO) as First Line Treatment in Patients With Metastatic Gastric or Gastroesophageal (GEJ) Adenocarcinoma.

The investigators hypothesize IXO chemotherapy will have an improvement in response rate and acceptable toxicity for uncurable metastatic gastric cancer compared to historical controls.

This is a single arm, open-label, multicentre, phase II trial in which patients with metastatic gastric or GEJ adenocarcinoma will be treated with the combination of irinotecan, capecitabine, and oxaliplatin (IXO).Patients will receive the combination of irinotecan, capecitabine, and oxaliplatin at the recommended phase II dose and sequence determined by the completed phase I trial. Patients will be treated on study until disease progression, overwhelming toxicity, or consent withdrawal.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Gastrointestinal Neoplasm
  • Gastric Adenocarcinoma
Drug: Irinotecan-Capecitabine-Oxaliplatin
Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
Other Name: Camptosar; Xeloda; Eloxatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
July 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • histologically documented gastric GEJ adenocarcinoma not previously treated with palliative systemic therapy.
  • Metastatic disease based on the presence of clinically and/or radiologically documented measurable disease based on RECIST.
  • ECOG performance status of 0,1 or 2.
  • Age ≥ 18 years
  • Life expectancy of least 3 months based on discretion of treating oncologist.
  • Adequate hematologic, hepatic, and renal function.
  • Patients who have received prior chemotherapy or radiation delivered as part of initial curative therapy (i.e. neoadjuvant or adjuvant chemotherapy administered alone and/or concurrently delivered with radiation and/or surgery) are permitted as long as that treatment was completed at least 6 months prior to study start date.
  • Patients may have received prior palliative radiotherapy (unless radiation was curative therapy to pelvis or to ≥25% of bone marrow stores) if this radiation was ≥ 4 weeks before study entry and patients must have recovered from the toxic effects of this treatment.
  • Patients may have received prior surgery if this surgery was ≥ 4 weeks before study entry and patients must have recovered from the toxic effects of this treatment.
  • Patients must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up.

Exclusion Criteria:

  • Patients who have received palliative chemotherapy for their metastatic gastric or GEJ tumor.
  • Prior treatment with > 6 cycles of traditional alkylating agent-based chemotherapy, > 2 cycles of carboplatin-based chemotherapy, prior treatment with irinotecan or oxaliplatin chemotherapy, or concurrent treatment with other experimental drugs or anti-cancer therapy.
  • Curative radiation treatment to the pelvis or radiation therapy to ≥ 25% of bone marrow stores.
  • Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, short gut syndrome, or history of bowel obstruction due to peritoneal metastases.
  • Previous of concurrent malignancies, excluding curatively treated in situ carcinoma of the cervix or non-melanoma skin cancer, unless at least 5 years have elapsed since last treatment and the patient is considered cured.
  • Any serious medical condition within 6 months prior to study entry such as myocardial infarction, uncontrolled congestive heart failure,unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, cerebrovascular diseases, uncontrolled hypertension, uncontrolled diabetes, uncontrolled psychiatric disorder, serious infection, active peptic ulcer disease, or other medical condition that .....
  • Gilbert's disease
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency.
  • Pre-existing neuropathy ≥ grade 2 from any cause.
  • Patients with unstable metastasis to the central nervous system are excluded. Patients who have treated brain metastasis and are off steroids, anticonvulsants, and have documented stability of lesions for at least 3 months may be eligible. A CT scan or MRI is NOT required to rule out brain metastases unless there is clinical suspicion of CNS involvement.
  • Pregnant of lactating women
Both
18 Years and older
No
Contact: Jennifer Spratlin, MD 780-432-8513 Jennifer.Spratlin@albertahealthservices.ca
Canada
 
NCT01129310
IXOGoo1 25412
Yes
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Sanofi
Study Chair: Jennifer Spratlin, MD AHS Cancer Control Alberta
AHS Cancer Control Alberta
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP